title: New TFO conjugates containing a carminomycinone-derived chromophore.
abstract: Conjugates obtained by linking the anthracycline intercalating chromophore to triple helix forming oligonucleotides (TFOs) have been used in a physicochemical study of the stability of triple helices with DNA sequences of pharmacological relevance. The intercalating moiety is represented by carminomycinone derivatives obtained upon O-demethylation and hydrolysis of the glycosidic linkage of daunomycin followed by the introduction of an alkylating residue at two different positions. Results of experiments with a polypurinic region present in the multidrug resistance (MDR) gene indicate that the stability of the triple helix is significantly enhanced by replacement of C's with (5-Me)C's in the TFO sequences tested. The stability is not changed when a 3'-TpT is present in place of a 3'-CpG at the presumed intercalation site of the anthraquinone chromophore. The same carminomycinone derivatives were used for the preparation of conjugates able to form triple helices with the polypurine tract (PPT) present in the human integrated genome of HIV-1 infected cells. Three different TFOs (T(4)(Me)CT(4)(Me)CC, C2; T(4)(Me)CT(4)(Me)CC(Me)CC(Me)CCT, C6; and T(4)(Me)CT(4)G(6), G6) were designed and linked to the anthraquinone moiety. These conjugates showed a significantly enhanced ability to bind the PPT region of HIV with respect to the nonconjugated TFOs.
authors.affiliation: ICOCEA-CNR, Via Gobetti 101, 40129 Bologna, Italy. capobianco@area.bo.cnr.it
authors.forename: M L
authors.initials: ML
authors.lastname: Capobianco
authors.forename: M
authors.initials: M
authors.lastname: De Champdoré
authors.forename: L
authors.initials: L
authors.lastname: Francini
authors.forename: S
authors.initials: S
authors.lastname: Lena
authors.forename: A
authors.initials: A
authors.lastname: Garbesi
authors.forename: F
authors.initials: F
authors.lastname: Arcamone
mesh_terms: D018943:Anthracyclines / Q000138:chemical synthesis* / Q000378:metabolism; D001483:Base Sequence / Q000502:physiology; D001665:Binding Sites / Q000502:physiology; D002360:Carubicin / Q000031:analogs & derivatives* / Q000737:chemistry* / Q000378:metabolism; D003630:Daunorubicin / Q000737:chemistry; D004355:Drug Stability; D019450:Genes, MDR / Q000235:genetics* / Q000502:physiology; D015497:HIV-1 / Q000737:chemistry / Q000235:genetics* / Q000378:metabolism; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007364:Intercalating Agents / Q000138:chemical synthesis / Q000378:metabolism; D009841:Oligonucleotides / Q000138:chemical synthesis* / Q000235:genetics; D011687:Purines / Q000737:chemistry / Q000378:metabolism
chemical_list: D018943:Anthracyclines; D007364:Intercalating Agents; D009841:Oligonucleotides; D011687:Purines; C015736:carminomycinone; D002360:Carubicin; D003630:Daunorubicin